TB-500 Biohacker and Longevity Stack Protocol: Dosing, Frequency, Cycles, and Evidence

What Is TB-500 and Why Are Biohackers Using It?

TB-500 is a synthetic peptide derived from thymosin beta-4, a 43-amino-acid protein found in virtually all human cells at measurable concentrations. The biologically active fragment spans amino acids 17 to 23 (the sequence LKKTETQ) and is responsible for most of the parent molecule's actin-regulatory and tissue-repair activity. Thymosin beta-4 was first isolated from thymic tissue in 1966 and has since appeared in over 700 peer-reviewed publications examining its roles in wound healing, angiogenesis, and inflammation modulation [1].

The longevity community's interest in TB-500 is grounded in a specific mechanistic story: actin polymerization governs cell migration, and TB-500 sequesters G-actin, which frees cells to migrate toward injury sites faster than they otherwise would [2]. Physicians in the Attia and Huberman tier of evidence-based performance medicine discuss tissue-repair peptides openly, and TB-500 has become one of the most-requested compounds among clients who also use GLP-1 agonists, low-dose rapamycin, or metformin as part of multi-modal longevity protocols.

The Thymosin Beta-4 Mechanism Relevant to Longevity

Thymosin beta-4 upregulates anti-apoptotic proteins and suppresses NFkB-mediated inflammatory signaling in cardiac, neural, and musculoskeletal tissue [3]. In rodent myocardial infarction models, intraperitoneal Tβ4 at 150 mg/kg reduced infarct size by approximately 26% and increased capillary density in the peri-infarct zone [4]. Those findings prompted early-phase veterinary and human compassionate-use exploration, though no Phase II or Phase III RCT in humans has been published as of early 2025.

Regulatory and Safety Framing

The FDA has not approved TB-500 for any human indication. It is classified as a research chemical in the United States [5]. The World Anti-Doping Agency (WADA) lists thymosin beta-4 and its fragments on the 2024 Prohibited List under Section S2 (Peptide Hormones, Growth Factors, Related Substances). Any athlete subject to drug testing should treat TB-500 use as a disqualifying substance.

Evidence Quality: What the Data Actually Shows

Biohacker communities sometimes present TB-500 as though the animal literature translates directly to human outcomes. That assumption deserves scrutiny.

Animal Studies (Strongest Available Data)

A 2010 study published in the Annals of the New York Academy of Sciences demonstrated that Tβ4 administered to rats with dermal wounds at 2 mg/kg accelerated re-epithelialization and collagen deposition compared with saline controls, with statistically significant differences at day 7 (P<0.01) [6]. A separate murine model of traumatic brain injury found that systemic Tβ4 at 6 mg/kg improved neurological severity scores by 40% at 28 days post-injury compared with vehicle [7].

Cardiac data comes largely from the laboratory of Deepak Srivastava at UCSF, whose group showed that Tβ4 primed epicardial progenitor cells to differentiate into functional cardiomyocytes after myocardial injury in mice [4]. This is the study most cited by longevity influencers. The effect was dose-dependent and required pre-treatment before injury, which has significant implications for the "stack it prophylactically" argument popular in longevity circles.

Human Data (Sparse)

RegeneRx Biopharmaceuticals ran a Phase II trial (NCT00016237) evaluating Tβ4 eye drops (RGN-259) in dry eye syndrome, with positive signals for epithelial healing [8]. A small Phase II cardiac study (NCT01311518) examined intravenous Tβ4 in patients with acute myocardial infarction and showed a favorable safety profile but did not reach statistical significance for the primary endpoint of left ventricular ejection fraction improvement at 4 months [9]. Neither trial used the subcutaneous route at the doses popularized by biohackers, and neither was designed as a longevity intervention.

Evidence Label Summary

| Claimed Benefit | Best Supporting Evidence | Evidence Level | |---|---|---| | Musculoskeletal repair | Rat/mouse wound models | Animal RCT | | Cardiac protection | Mouse MI models, 1 small human Phase II | Animal RCT / early human | | Neurological recovery | Mouse TBI models | Animal RCT | | Flexibility / connective tissue | Anecdotal, no controlled data | Practitioner anecdote | | Anti-aging / longevity | Mechanistic hypothesis only | Preclinical hypothesis |

Standard Biohacker Dosing Protocol

There is no FDA-cleared dosing guideline for TB-500 in humans. The protocol below synthesizes published animal pharmacokinetics, the RegeneRx clinical trial dosing ranges converted to typical human body weight, and the practitioner frameworks that have emerged in clinical peptide medicine over the past decade. Treat every dose figure here as practitioner-grade guidance, not regulatory approval.

Loading Phase

The loading phase runs 4 to 6 weeks and aims to saturate tissue receptors and establish measurable circulating Tβ4 levels.

• Dose: 2 to 4 mg per injection
• Frequency: Twice per week (e.g., Monday and Thursday)
• Route: Subcutaneous, rotated sites (abdomen or lateral thigh preferred; near-injury site injections are sometimes used but add no proven benefit over systemic administration)
• Reconstitution: Add 2.0 mL bacteriostatic water to a 5 mg vial to yield a concentration of 2.5 mg/mL. A 4 mg dose therefore requires 1.6 mL drawn into a 29-gauge insulin syringe.

A 75 kg individual running 4 mg twice weekly reaches approximately 0.107 mg/kg per dose. Rodent studies showing tissue-repair effects used 2 to 6 mg/kg, suggesting the human biohacker dose may be sub-pharmacological relative to animal data. This is an honest limitation that longevity influencers rarely acknowledge.

Maintenance Phase

After the loading cycle, most practitioners reduce to a maintenance schedule to sustain benefits while limiting cumulative peptide exposure.

• Dose: 2 to 2.5 mg per injection
• Frequency: Once per week
• Duration: 4 to 8 weeks, followed by a 4 to 8 week off cycle before reassessment

Cycle-Off and Rest Periods

TB-500 does not suppress endogenous hormone production the way anabolic steroids do, so the rationale for a hard cycle-off is precautionary rather than pharmacologically mandated. The concern is theoretical receptor desensitization and the absence of long-term human safety data. A 1:1 on-to-off ratio (e.g., 8 weeks on, 8 weeks off) is the conservative approach.

Injection Technique

1. Wipe the vial septum and injection site with an alcohol swab. Allow 30 seconds to dry.
2. Draw air equal to the volume you will withdraw, inject into the vial, then pull the peptide solution.
3. Pinch skin, insert needle at a 45-degree angle, inject slowly over 5 to 10 seconds.
4. Remove needle, apply gentle pressure. Do not rub.
5. Rotate sites each injection to prevent lipodystrophy.

The Biohacker Stack: Combining TB-500 with Other Compounds

The longevity community rarely uses TB-500 in isolation. The following framework reflects how TB-500 is most commonly layered with other compounds, organized by mechanism and supporting rationale. This framework was developed by the HealthRX medical team based on practitioner consultation and published mechanistic literature; it has not been tested in a controlled trial.

TB-500 and BPC-157

BPC-157 (body protection compound 157) is a pentadecapeptide derived from human gastric juice that promotes angiogenesis and modulates dopaminergic pathways [10]. Combined with TB-500, the working hypothesis is complementary tissue repair: TB-500 drives actin-mediated cell migration while BPC-157 accelerates new vessel formation into the repair zone. Animal studies support each mechanism individually [10, 11]; no human trial has examined the combination.

A common practitioner protocol pairs 250 to 500 mcg of BPC-157 subcutaneously once daily with the TB-500 loading schedule. The two peptides are drawn into separate syringes and injected at separate sites because mixing stability data is unavailable.

TB-500 and GHK-Cu

GHK-Cu (copper peptide) is a naturally occurring plasma tripeptide with evidence for fibroblast stimulation and antioxidant gene expression via Nrf2 upregulation [12]. It is often added to peptide stacks as a topical or subcutaneous adjunct for skin and connective tissue health. At 1 to 2 mg subcutaneous two to three times per week, it is mechanistically distinct from TB-500 and unlikely to create additive receptor competition.

TB-500 and Longevity Pharmacologics

Some practitioners layer TB-500 onto a background of low-dose rapamycin (2 to 6 mg once weekly) or metformin (500 to 1,000 mg daily). The theoretical logic is that rapamycin's mTORC1 inhibition may reduce the pro-growth signaling that, in theory, could become problematic with repeated peptide use. This is speculative. Rapamycin's own evidence base for longevity in humans remains limited to mechanistic studies and observational data; no published RCT has established a mortality benefit in non-immunosuppression human populations [13].

NAD+ precursors (nicotinamide riboside at 300 to 500 mg/day or NMN at 250 to 500 mg/day) are frequently added for mitochondrial support. They do not interact with TB-500's mechanism directly, and the stack is more additive-by-aspiration than additive-by-mechanism.

Monitoring Labs: What to Check and When

Because TB-500 has no established human safety profile in long-term use, monitoring is the responsible minimum for any practitioner overseeing this protocol.

Baseline Panel (Before Starting)

• CBC with differential: Establish baseline immune cell counts; thymosin peptides modulate T-cell activity [1], and any unexpected lymphocytic shift should prompt pause.
• CMP (comprehensive metabolic panel): Renal and hepatic function baseline.
• CRP (high-sensitivity): Inflammatory baseline. TB-500's purported benefit is anti-inflammatory; tracking hsCRP gives a quantitative signal to assess whether the peptide is doing anything measurable.
• ESR and fibrinogen: Additional inflammatory markers useful for musculoskeletal applications.
• PSA (for males over 40): Not directly related to TB-500, but standard practice before initiating any peptide protocol given angiogenic properties.
• CBC differential with natural killer cell percentage: TB-500 has shown immunomodulatory effects in murine models; NK cell percentage gives a rough immune health marker [3].

Mid-Cycle Check (Week 4)

Repeat hsCRP, CBC, and CMP. A clinically significant rise in CRP (>2 mg/L above baseline) or any new cytopenias should prompt cycle suspension and physician review.

End-of-Cycle Panel (Week 8 or Cycle End)

Full repeat of the baseline panel. Document any symptomatic changes. If no measurable change in hsCRP and no symptomatic improvement in the targeted tissue complaint after two full cycles, reassess whether TB-500 is providing benefit in this individual.

Expected Timeline of Outcomes

Animal pharmacokinetics and anecdotal practitioner reports suggest the following rough timeline. These are estimates, not guarantees, and individual variation is substantial.

• Weeks 1 to 2: Mild reduction in localized inflammation at injury sites; some users report improved joint mobility. Likely reflects anti-inflammatory rather than structural effects.
• Weeks 3 to 4: Accelerated tissue repair in active injuries; improved recovery time between training sessions. This is the window most practitioners report the most subjective feedback.
• Weeks 5 to 8: Potential connective tissue remodeling effects. Tendons and ligaments have poor vascularity and slower turnover; structural change here, if real, takes longer than muscle.
• Post-cycle (maintenance): Sustained flexibility and reduced baseline inflammation in responders. Non-responders should not extend cycles past 12 weeks without a specific clinical rationale.

The Endocrine Society has not issued guidelines on thymosin peptides for longevity, and the American Academy of Anti-Aging Medicine's position statements on peptide therapy vary by practitioner [14]. Anyone presenting the timeline above as certain is overstating the evidence.

Practical Reconstitution and Storage

Lyophilized TB-500 powder is stable at room temperature for short shipping periods but should be stored at 2 to 8°C (standard refrigerator) upon receipt. After reconstitution with bacteriostatic water, the solution is stable for up to 28 days refrigerated and should be discarded after that window.

Never reconstitute with sterile water (no preservative) if the vial will be used across multiple injections; bacteriostatic water contains 0.9% benzyl alcohol to prevent microbial growth between uses. Draw the reconstitution volume slowly along the vial wall to avoid creating foam, which can degrade the peptide.

Vial labeling should include the reconstitution date and concentration (e.g., "TB-500, 2.5 mg/mL, reconstituted 2025-01-28"). Discard any solution that appears cloudy or particulate.

Who Should Not Use TB-500

Several contraindications deserve explicit statement.

• Active or recent malignancy. TB-500 promotes angiogenesis and cell migration. These are the same mechanisms exploited by tumors. Anyone with a current or recent cancer diagnosis should not use TB-500 without explicit oncology clearance, and that clearance would be unusual [4].
• Pregnancy and breastfeeding. No safety data exists. Thymosin peptides cross cellular membranes and their effects on fetal development are unstudied.
• Competitive athletes. WADA prohibition applies regardless of perceived therapeutic intent.
• Age <18. Endogenous growth factor signaling is already elevated in adolescents; exogenous peptide augmentation carries theoretical harm with zero supporting safety data.
• Uncontrolled autoimmune disease. Immunomodulatory effects of Tβ4 are bidirectional in some models; a person with poorly controlled lupus or rheumatoid arthritis could experience unpredictable immune shifts [3].

A Note on Sourcing and Compounding Quality

Peptide purity is not regulated for research chemicals sold in the United States. A 2019 analysis of commercially available "research peptide" products found that only 45.5% of samples tested contained the labeled peptide at >95% purity, with several samples containing unidentified peptide fragments [15]. Sourcing from a compounding pharmacy that operates under 503A or 503B FDA guidelines provides a higher (though not guaranteed) purity assurance than gray-market research chemical vendors.

The FDA issued warning letters to several peptide compounding pharmacies between 2020 and 2024 for cGMP violations [5]. Reviewing a Certificate of Analysis (CoA) from a third-party lab for each batch is the minimum quality standard a practitioner should require before recommending any compounded peptide to a patient.